NCT07670416 Enicepatide Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready landscape. This focused report examines NCT07670416—A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why NCT07670416 is a hot trial to watch
Diabetes Mellitus, Type 2 is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. NCT07670416 is notable because it evaluates Enicepatide in a Phase 3 design while Percent Change From Baseline in Body Weight at Week 52 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07670416 |
| Official title | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes |
| Phase / status | Phase 3 / Recruiting |
| Intervention | Enicepatide, Placebo |
| Sponsor | Not reported |
| Collaborators | Not reported |
| Geography | China |
| Enrollment | 300 |
| Primary endpoint | Percent Change From Baseline in Body Weight at Week 52 |
| Endpoint time frame | Baseline through Week 52 |
| Primary completion / readout proxy | [object Object] |
Design and endpoint interpretation
The phase label is only the starting point. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of 300 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary: Percent Change From Baseline in Body Weight at Week 52 (Baseline through Week 52)
- Secondary: Percentage of Participants Achieving ≥5% Body Weight Loss at Week 52 (At Week 52)
- Secondary: Percentage of Participants Achieving ≥10% Body Weight Loss at Week 52 (At Week 52)
- Secondary: Percentage of Participants Achieving ≥15% Body Weight Loss at Week 52 (At Week 52)
- Secondary: Percentage of Participants Achieving ≥20% Body Weight Loss, in Participants Receiving Enicepatide Dose 2 and Dose 3 (At Week 52)
Benchmark readouts in the surrounding field
- The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) (Phase 3): Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 801 participants ; Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] = 862 participants
- A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes (Phase 3): Change in Glycated Haemoglobin (HbA1c)(Mean) = -0.84 Percentage (%) point (Standard Deviation, 0.83); Change in Glycated Haemoglobin (HbA1c)(Mean): Treatment difference = -0.21(95% CI, -0.36 to -0.07), P-Value = <0.0001
- A Phase 3, Long-term Safety Study of LY3502970 in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone or in Combination With Oral Antihyperglycemic Medications (ACHIEVE-J) (Phase 3): Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 114 Participants ; Number of Participants With Treatment Emergent Adverse Events (TEAEs) = 107 Participants
These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.
Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Enicepatide (Phase 3; GIPR x GLP-1R)
Company & Deal Intelligence context: Not reported
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.
Bottom line
NCT07670416 is a focused lens on Diabetes Mellitus, Type 2 development. Its value will be determined by whether Enicepatide can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
